Repotrectinib

• CAT Number: I011866
• CAS Number: 1802220-02-5
• Molecular Formula: C18H18FN5O2
• Molecular Weight: 355.37
• Purity: 98%
• Synonyms: TPX-0005; Augtyro
• Target: ROS1, pan-TRK, ALK
• Target Protein: P08922,P04629
• Appearance: Solid
• Storage: Dry, dark and at 2 - 8 °C for six months or -20°C for two years.
• IC50: YU1078 cells ：IC50, 0.021 µM
• IUPAC Name: (3R,11S)-6-fluoro-3,11-dimethyl-10-oxa-2,13,17,18,21-pentazatetracyclo[13.5.2.04,9.018,22]docosa-1(21),4(9),5,7,15(22),16,19-heptaen-14-one
• InChI: InChI=1S/C18H18FN5O2/c1-10-8-20-18(25)14-9-21-24-6-5-16(23-17(14)24)22-11(2)13-7-12(19)3-4-15(13)26-10/h3-7,9-11H,8H2,1-2H3,(H,20,25)(H,22,23)/t10-,11+/m0/s1
• InChIKey: FIKPXCOQUIZNHB-WDEREUQCSA-N
• SMILES: C[C@H]1CNC(=O)C2=C3N=C(C=CN3N=C2)N[C@@H](C4=C(O1)C=CC(=C4)F)C

Repotrectinib（Cat No.:I011866）is a next-generation tyrosine kinase inhibitor (TKI) designed to target ROS1, TRK, and ALK mutations in cancer, particularly non-small cell lung cancer (NSCLC). It exhibits high potency against these oncogenic drivers, including resistance mutations, offering a promising therapeutic option for patients with ROS1-positive NSCLC or NTRK fusion-positive tumors. With its ability to overcome resistance to prior TKIs, Repotrectinib addresses an unmet need in precision oncology. Its favorable safety profile and clinical efficacy make it a valuable candidate for treating advanced, mutation-driven cancers.